Endocrine Abstracts

Aims: Our aim was to explore predictive factors for the pleiotropic responses to exenatide during the first 12 weeks of therapy, and associations between these responses.Methods: This was an observational study based on patients (n=83) with type 2 diabetes mellitus (T2D) in whom exenatide had been added to existing oral hypoglycaemic therapy. Exenatide was administered subcutaneously (5 mcg bd for the first month, 10 mcg bd thereafter). Data colle...